Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.
Fifteen patients with measurable metastatic transitional cell bladder cancer were treated with VP 16-213 100 mg/m2 IV daily for 4 days, repeated every 3 weeks. There were no complete or partial (greater than 50% reduction in area, maintained for 6 weeks) responses. Two patients showed transient reduction by 50% in the area of measurable lesions, and a further five patients showed brief stabilisation of previously progressive disease. The treatment was well tolerated. In two patients, total WBC at the nadir fell below 1.0 X 10(9)/l but without complications from infection. We conclude that VP 16-213 is inactive in metastatic transitional cell urothelial cancer.
D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005047:Etoposide / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D011034:Podophyllotoxin